Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Eli Lilly’s Alzheimer’s disease (AD) drug donanemab has been recommended by the European Medicines Agency’s human medicines ...

Kisunla, a newly approved Alzheimer's drug in Taiwan, would not be covered by the National Health Insurance (NHI) system, ...

Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.